Loading…

Serological biomarker profiles of rapidly progressive osteoarthritis in tanezumab-treated patients

There is a need for efficacious and safe pain treatments for OA (osteoarthritis). The nerve growth factor (NGF) antibody tanezumab is associated with high efficacy, but when combined with chronic NSAID treatment shows an increased risk of rapidly progressive osteoarthritis (RPOA) in a small group of...

Full description

Saved in:
Bibliographic Details
Published in:Osteoarthritis and cartilage 2019-03, Vol.27 (3), p.484-492
Main Authors: Karsdal, M.A., Verburg, K.M., West, C.R., Bay-Jensen, A.C., Keller, D.S., Arends, R.H.G.P.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c400t-4c6d36dac36eb339409db78fc09b65f107b1575288ff51f29df8b86794fc732c3
cites cdi_FETCH-LOGICAL-c400t-4c6d36dac36eb339409db78fc09b65f107b1575288ff51f29df8b86794fc732c3
container_end_page 492
container_issue 3
container_start_page 484
container_title Osteoarthritis and cartilage
container_volume 27
creator Karsdal, M.A.
Verburg, K.M.
West, C.R.
Bay-Jensen, A.C.
Keller, D.S.
Arends, R.H.G.P.
description There is a need for efficacious and safe pain treatments for OA (osteoarthritis). The nerve growth factor (NGF) antibody tanezumab is associated with high efficacy, but when combined with chronic NSAID treatment shows an increased risk of rapidly progressive osteoarthritis (RPOA) in a small group of patients. The aim of this study was to phenotype with biochemical biomarkers of bone, cartilage, soft tissue, synovial metabolism OA patients who are at risk of developing RPOA type-2, for both limited and chronic NSAIDs users. The dataset consisted of OA patients participating in tanezumab trials who used NSAIDs
doi_str_mv 10.1016/j.joca.2018.12.001
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2159987944</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1063458418315541</els_id><sourcerecordid>2159987944</sourcerecordid><originalsourceid>FETCH-LOGICAL-c400t-4c6d36dac36eb339409db78fc09b65f107b1575288ff51f29df8b86794fc732c3</originalsourceid><addsrcrecordid>eNp9kEtLJDEURoM4-Br_gAuppZuquUkq9QA3Ir5AmMXMrEMeN5q2utMmacH59abo1qWrXMK5H_c7hJxRaCjQ7teiWQSjGgZ0aChrAOgeOaKCsXrsBN8vM3S8bsXQHpLjlBYAwCmFA3LIQfRdP7ZHRP_BGKbw5I2aKu3DUsUXjNU6BucnTFVwVVRrb6f3-e8pYkr-DauQMgYV83P02afKr6qsVvh_s1S6zhFVRlutVfa4yukn-eHUlPB0956Qf7c3f6_v68ffdw_XV4-1aQFy3ZrO8s4qwzvUnI8tjFb3gzMw6k44Cr2mohdsGJwT1LHRukEPcwtnes4MPyEX29xy6OsGU5ZLnwxOU7ksbJJkVIzjUPi2oGyLmhhSiujkOvpS_V1SkLNbuZCzWzm7lZTJ4rYsne_yN3qJ9mvlU2YBLrcAlpZvHqNMphgwaH1Ek6UN_rv8D8eFjOM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2159987944</pqid></control><display><type>article</type><title>Serological biomarker profiles of rapidly progressive osteoarthritis in tanezumab-treated patients</title><source>ScienceDirect Freedom Collection</source><creator>Karsdal, M.A. ; Verburg, K.M. ; West, C.R. ; Bay-Jensen, A.C. ; Keller, D.S. ; Arends, R.H.G.P.</creator><creatorcontrib>Karsdal, M.A. ; Verburg, K.M. ; West, C.R. ; Bay-Jensen, A.C. ; Keller, D.S. ; Arends, R.H.G.P.</creatorcontrib><description>There is a need for efficacious and safe pain treatments for OA (osteoarthritis). The nerve growth factor (NGF) antibody tanezumab is associated with high efficacy, but when combined with chronic NSAID treatment shows an increased risk of rapidly progressive osteoarthritis (RPOA) in a small group of patients. The aim of this study was to phenotype with biochemical biomarkers of bone, cartilage, soft tissue, synovial metabolism OA patients who are at risk of developing RPOA type-2, for both limited and chronic NSAIDs users. The dataset consisted of OA patients participating in tanezumab trials who used NSAIDs &lt;90 days (limited NSAID users) or chronic users (NSAIDs ≥90 days) over an average 10 month period. Biomarker data were available for 47 cases (RPOA type-2) and 92 controls. Non-linear and linear multivariable predictive models were developed. By use of two biomarkers at baseline the receiver operating characteristic (ROC) curve area for RPOA type-2 in limited NSAID users was 71%, [CI] (60–83%). OA subjects with this biomarker phenotype had 8-fold higher confidence interval [CI][(2–33)] relative risk of developing RPOA type-2 as compared to OA patients without this phenotype. The AUC of the model in chronic NSAIDs users based on 5 biomarkers was 78%, [CI](69–88%), with 4-fold [CI (2–6)] relative risk of developing RPOA type-2. In this hypothesis generating and exploratory study, we identified combinations of biomarkers associated with OA patients who develop RPOA type-2, which may be related to the pathology of the RPOA type-2 joint.</description><identifier>ISSN: 1063-4584</identifier><identifier>EISSN: 1522-9653</identifier><identifier>DOI: 10.1016/j.joca.2018.12.001</identifier><identifier>PMID: 30576794</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Biomarker ; Clinical study ; Osteoarthritis ; RPOA2 ; THR</subject><ispartof>Osteoarthritis and cartilage, 2019-03, Vol.27 (3), p.484-492</ispartof><rights>2018</rights><rights>Copyright © 2018. Published by Elsevier Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c400t-4c6d36dac36eb339409db78fc09b65f107b1575288ff51f29df8b86794fc732c3</citedby><cites>FETCH-LOGICAL-c400t-4c6d36dac36eb339409db78fc09b65f107b1575288ff51f29df8b86794fc732c3</cites><orcidid>0000-0002-4764-5100 ; 0000-0001-7952-9297</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30576794$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Karsdal, M.A.</creatorcontrib><creatorcontrib>Verburg, K.M.</creatorcontrib><creatorcontrib>West, C.R.</creatorcontrib><creatorcontrib>Bay-Jensen, A.C.</creatorcontrib><creatorcontrib>Keller, D.S.</creatorcontrib><creatorcontrib>Arends, R.H.G.P.</creatorcontrib><title>Serological biomarker profiles of rapidly progressive osteoarthritis in tanezumab-treated patients</title><title>Osteoarthritis and cartilage</title><addtitle>Osteoarthritis Cartilage</addtitle><description>There is a need for efficacious and safe pain treatments for OA (osteoarthritis). The nerve growth factor (NGF) antibody tanezumab is associated with high efficacy, but when combined with chronic NSAID treatment shows an increased risk of rapidly progressive osteoarthritis (RPOA) in a small group of patients. The aim of this study was to phenotype with biochemical biomarkers of bone, cartilage, soft tissue, synovial metabolism OA patients who are at risk of developing RPOA type-2, for both limited and chronic NSAIDs users. The dataset consisted of OA patients participating in tanezumab trials who used NSAIDs &lt;90 days (limited NSAID users) or chronic users (NSAIDs ≥90 days) over an average 10 month period. Biomarker data were available for 47 cases (RPOA type-2) and 92 controls. Non-linear and linear multivariable predictive models were developed. By use of two biomarkers at baseline the receiver operating characteristic (ROC) curve area for RPOA type-2 in limited NSAID users was 71%, [CI] (60–83%). OA subjects with this biomarker phenotype had 8-fold higher confidence interval [CI][(2–33)] relative risk of developing RPOA type-2 as compared to OA patients without this phenotype. The AUC of the model in chronic NSAIDs users based on 5 biomarkers was 78%, [CI](69–88%), with 4-fold [CI (2–6)] relative risk of developing RPOA type-2. In this hypothesis generating and exploratory study, we identified combinations of biomarkers associated with OA patients who develop RPOA type-2, which may be related to the pathology of the RPOA type-2 joint.</description><subject>Biomarker</subject><subject>Clinical study</subject><subject>Osteoarthritis</subject><subject>RPOA2</subject><subject>THR</subject><issn>1063-4584</issn><issn>1522-9653</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp9kEtLJDEURoM4-Br_gAuppZuquUkq9QA3Ir5AmMXMrEMeN5q2utMmacH59abo1qWrXMK5H_c7hJxRaCjQ7teiWQSjGgZ0aChrAOgeOaKCsXrsBN8vM3S8bsXQHpLjlBYAwCmFA3LIQfRdP7ZHRP_BGKbw5I2aKu3DUsUXjNU6BucnTFVwVVRrb6f3-e8pYkr-DauQMgYV83P02afKr6qsVvh_s1S6zhFVRlutVfa4yukn-eHUlPB0956Qf7c3f6_v68ffdw_XV4-1aQFy3ZrO8s4qwzvUnI8tjFb3gzMw6k44Cr2mohdsGJwT1LHRukEPcwtnes4MPyEX29xy6OsGU5ZLnwxOU7ksbJJkVIzjUPi2oGyLmhhSiujkOvpS_V1SkLNbuZCzWzm7lZTJ4rYsne_yN3qJ9mvlU2YBLrcAlpZvHqNMphgwaH1Ek6UN_rv8D8eFjOM</recordid><startdate>20190301</startdate><enddate>20190301</enddate><creator>Karsdal, M.A.</creator><creator>Verburg, K.M.</creator><creator>West, C.R.</creator><creator>Bay-Jensen, A.C.</creator><creator>Keller, D.S.</creator><creator>Arends, R.H.G.P.</creator><general>Elsevier Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-4764-5100</orcidid><orcidid>https://orcid.org/0000-0001-7952-9297</orcidid></search><sort><creationdate>20190301</creationdate><title>Serological biomarker profiles of rapidly progressive osteoarthritis in tanezumab-treated patients</title><author>Karsdal, M.A. ; Verburg, K.M. ; West, C.R. ; Bay-Jensen, A.C. ; Keller, D.S. ; Arends, R.H.G.P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c400t-4c6d36dac36eb339409db78fc09b65f107b1575288ff51f29df8b86794fc732c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Biomarker</topic><topic>Clinical study</topic><topic>Osteoarthritis</topic><topic>RPOA2</topic><topic>THR</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Karsdal, M.A.</creatorcontrib><creatorcontrib>Verburg, K.M.</creatorcontrib><creatorcontrib>West, C.R.</creatorcontrib><creatorcontrib>Bay-Jensen, A.C.</creatorcontrib><creatorcontrib>Keller, D.S.</creatorcontrib><creatorcontrib>Arends, R.H.G.P.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Osteoarthritis and cartilage</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Karsdal, M.A.</au><au>Verburg, K.M.</au><au>West, C.R.</au><au>Bay-Jensen, A.C.</au><au>Keller, D.S.</au><au>Arends, R.H.G.P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Serological biomarker profiles of rapidly progressive osteoarthritis in tanezumab-treated patients</atitle><jtitle>Osteoarthritis and cartilage</jtitle><addtitle>Osteoarthritis Cartilage</addtitle><date>2019-03-01</date><risdate>2019</risdate><volume>27</volume><issue>3</issue><spage>484</spage><epage>492</epage><pages>484-492</pages><issn>1063-4584</issn><eissn>1522-9653</eissn><abstract>There is a need for efficacious and safe pain treatments for OA (osteoarthritis). The nerve growth factor (NGF) antibody tanezumab is associated with high efficacy, but when combined with chronic NSAID treatment shows an increased risk of rapidly progressive osteoarthritis (RPOA) in a small group of patients. The aim of this study was to phenotype with biochemical biomarkers of bone, cartilage, soft tissue, synovial metabolism OA patients who are at risk of developing RPOA type-2, for both limited and chronic NSAIDs users. The dataset consisted of OA patients participating in tanezumab trials who used NSAIDs &lt;90 days (limited NSAID users) or chronic users (NSAIDs ≥90 days) over an average 10 month period. Biomarker data were available for 47 cases (RPOA type-2) and 92 controls. Non-linear and linear multivariable predictive models were developed. By use of two biomarkers at baseline the receiver operating characteristic (ROC) curve area for RPOA type-2 in limited NSAID users was 71%, [CI] (60–83%). OA subjects with this biomarker phenotype had 8-fold higher confidence interval [CI][(2–33)] relative risk of developing RPOA type-2 as compared to OA patients without this phenotype. The AUC of the model in chronic NSAIDs users based on 5 biomarkers was 78%, [CI](69–88%), with 4-fold [CI (2–6)] relative risk of developing RPOA type-2. In this hypothesis generating and exploratory study, we identified combinations of biomarkers associated with OA patients who develop RPOA type-2, which may be related to the pathology of the RPOA type-2 joint.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>30576794</pmid><doi>10.1016/j.joca.2018.12.001</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-4764-5100</orcidid><orcidid>https://orcid.org/0000-0001-7952-9297</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1063-4584
ispartof Osteoarthritis and cartilage, 2019-03, Vol.27 (3), p.484-492
issn 1063-4584
1522-9653
language eng
recordid cdi_proquest_miscellaneous_2159987944
source ScienceDirect Freedom Collection
subjects Biomarker
Clinical study
Osteoarthritis
RPOA2
THR
title Serological biomarker profiles of rapidly progressive osteoarthritis in tanezumab-treated patients
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T06%3A32%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Serological%20biomarker%20profiles%20of%20rapidly%20progressive%20osteoarthritis%20in%20tanezumab-treated%20patients&rft.jtitle=Osteoarthritis%20and%20cartilage&rft.au=Karsdal,%20M.A.&rft.date=2019-03-01&rft.volume=27&rft.issue=3&rft.spage=484&rft.epage=492&rft.pages=484-492&rft.issn=1063-4584&rft.eissn=1522-9653&rft_id=info:doi/10.1016/j.joca.2018.12.001&rft_dat=%3Cproquest_cross%3E2159987944%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c400t-4c6d36dac36eb339409db78fc09b65f107b1575288ff51f29df8b86794fc732c3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2159987944&rft_id=info:pmid/30576794&rfr_iscdi=true